Showing 241-250 of 9926 results for "".
DermwireTV: FDA Approves Humira Biosimilar; Study Examines Trifarotene for Acne Lesions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approves-humira-biosimilar-study-examines-trifarotene-acne-lesions/24513/In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD; and the PA Perspective series addresses buildinHow to Discuss Isotretinoin’s Safety Profile With Acne Patients
https://practicaldermatology.com/conferences/maui-derm-2024/how-to-discuss-isotretinoins-safety-profile-with-acne-patients/20237/Acne Symposium moderator Guy Webster, MD, PhD, clinical professor of dermatology at Thomas Jefferson University, explains how he helps adolescent patients with the most severe cases of acne manage the potential side effects of isotretinoin.Key Components of an Effective Strategic Plan
https://practicaldermatology.com/topics/practice-management/key-components-of-an-effective-strategic-plan/23933/A number of actionable steps can effectively and efficiently ensure that your practice stays on track.A Dermatologist’s Guide to Marketing Skin Cancer Screenings
https://practicaldermatology.com/topics/practice-management/a-dermatologists-guide-to-marketing-skin-cancer-screenings/23932/As the mercury soars, bring prevention and professional skin checks out of the shadows and into the light.At Your Service: Championing Employee Leadership
https://practicaldermatology.com/topics/practice-management/at-your-service-championing-employee-leadership/23793/How to develop engaged staff members who perform at the owner level.DermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)Estrogen and Skin: What Can We Do
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/estrogen-and-skin-what-can-we-do/20123/There’s accumulated evidence that depletion of estrogen with age contributes to the visible signs of skin aging. But dermatologists haven’t had many treatment options—until now. Joel L. Cohen, MD addresses the latest developments in care for estrogen deficient skin.Top Tips for Increasing Social Media Engagement
https://practicaldermatology.com/topics/practice-management/top-tips-for-increasing-social-media-engagement/23709/It takes time to grow your base, but if you know your audience and strategize, you can see gains.DermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyCosmetic Surgery Forum: 2021 Recap
https://practicaldermatology.com/topics/skin-cancer-photoprotection/cosmetic-surgery-forum-2021-recap/20032/Cosmetic Surgery Forum founder and director Joel Schlessinger, MD offers an overview of the 2021 conference in Nashville.